Abstract
Alzheimers disease has become one of the most serious healthcare problems nowadays, where age is clearly the major risk factor. The pathology of the disease is characterized by the formation of senile plaques outside the neurons, which are composed, predominantly, by the β-amyloid (Aβ) peptide. Considering that β-secretase is an aspartyl protease involved in the cleavage of the amyloid precursor, the first step required for the formation of Aβ, becomes an attractive therapeutic target for drug design. A virtual screening approach based on flexible docking was applied in order to identify potential inhibitor candidates of β-secretase, since the docking method used here showed to be able to reproduce the binding modes of crystallographic complexes. After validation, ten potential inhibitors were selected and evaluated with respect to the analysis of toxicological groups. The most promising inhibitor candidate was analyzed in a molecular dynamics trajectory to reinforce, theoretically, the potential inhibitory activity. Overall results obtained here suggest that this novel potential β-secretase inhibitor could be a promising pharmaceutical for the Alzheimers disease treatment.
Current Bioactive Compounds
Title: In Silico Search and Toxicology Prediction of Novel Potential β-Secretase Inhibitors in Alzheimers Disease
Volume: 5 Issue: 2
Author(s): Vinicius Barreto da Silva, Adriana Mieco Namba, Daniela Godoy Pantalena, Taina Ferreira do Prado and Carlos Henrique Tomich de Paula da Silva
Affiliation:
Abstract: Alzheimers disease has become one of the most serious healthcare problems nowadays, where age is clearly the major risk factor. The pathology of the disease is characterized by the formation of senile plaques outside the neurons, which are composed, predominantly, by the β-amyloid (Aβ) peptide. Considering that β-secretase is an aspartyl protease involved in the cleavage of the amyloid precursor, the first step required for the formation of Aβ, becomes an attractive therapeutic target for drug design. A virtual screening approach based on flexible docking was applied in order to identify potential inhibitor candidates of β-secretase, since the docking method used here showed to be able to reproduce the binding modes of crystallographic complexes. After validation, ten potential inhibitors were selected and evaluated with respect to the analysis of toxicological groups. The most promising inhibitor candidate was analyzed in a molecular dynamics trajectory to reinforce, theoretically, the potential inhibitory activity. Overall results obtained here suggest that this novel potential β-secretase inhibitor could be a promising pharmaceutical for the Alzheimers disease treatment.
Export Options
About this article
Cite this article as:
da Silva Barreto Vinicius, Namba Mieco Adriana, Pantalena Godoy Daniela, do Prado Ferreira Taina and de Paula da Silva Tomich Carlos Henrique, In Silico Search and Toxicology Prediction of Novel Potential β-Secretase Inhibitors in Alzheimers Disease, Current Bioactive Compounds 2009; 5 (2) . https://dx.doi.org/10.2174/157340709788452000
DOI https://dx.doi.org/10.2174/157340709788452000 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preservation of Cellular Glutathione Status and Mitochondrial Membrane Potential by N-Acetylcysteine and Insulin Sensitizers Prevent Carbonyl Stress-Induced Human Brain Endothelial Cell Apoptosis
Current Neurovascular Research Carbon Monoxide and the Brain: Time to Rethink the Dogma
Current Pharmaceutical Design Can Diet and Physical Activity Limit Alzheimer's Disease Risk?
Current Alzheimer Research Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease
Current Alzheimer Research Physiologic Tailoring of Treatment in Resistant Hypertension
Current Cardiology Reviews Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Early and Mild Phases of Primary Progressive Aphasia: A Case Series
Current Aging Science Targeting Mitochondrial Bioenergetics for Alzheimers Prevention and Treatment
Current Pharmaceutical Design Advances in Bioconjugation
Current Organic Chemistry Cardiomyopathy of Pregnancy
Current Women`s Health Reviews Behcets Syndrome: Literature Review
Current Rheumatology Reviews Microtubules (tau) as an Emerging Therapeutic Target: NAP (Davunetide)
Current Pharmaceutical Design 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Role of the Transglutaminase Enzymes in the Nervous System and their Possible Involvement in Neurodegenerative Diseases
Current Medicinal Chemistry MAPKs as Mediators of Cell Fate Determination: an Approach to Neurodegenerative Diseases
Current Medicinal Chemistry Multiple Defects in Energy Metabolism in Alzheimers Disease
Current Drug Targets Screening for Rare Genetic Variants Associated with Atherosclerosis: Opportunity for Personalized Medicine
Current Vascular Pharmacology Combination of Phytosterols and Omega-3 Fatty Acids: A Potential Strategy to Promote Cardiovascular Health
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Protection Mechanisms Against Aβ42 Aggregation
Current Alzheimer Research